Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction

Transfusion

Volumn 53, Issue 10, 2013, Pages 2168-2175

  Hewitt, Patricia E ^a   Davison, Katy ^b   Howell, David R ^b   Taylor, Graham P ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD COMPONENT; BLOOD DONOR; ERYTHROCYTE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; LEUKAPHERESIS; MAJOR CLINICAL STUDY; THROMBOCYTE;

DELTARETROVIRUS; DELTARETROVIRUS INFECTIONS; FEMALE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MALE; MIDDLE AGED;

EID: 84885843615     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12105     Document Type: Article

References (20)

1. Davison KL, Dow B, Barbara JA, Hewitt PE, Eglin R,. The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006. Transfus Med 2009; 19: 24-34.
2. Davidson F, Lycett C, Jarvis LM, Kerr D, Lumley S, Petrik J, Dow BC,. Detection of HTLV-I and -II in Scottish blood donor samples and archive donations. Vox Sang 2006; 91: 231-236. (Pubitemid 44337280)
3. The English National Blood Service HCV Lookback Collaboration Collaborators. Transfusion transmission of HCV infection before anti-HCV testing of blood donations in England: results of the national HCV lookback programme. Transfusion 2001; 42: 1146-1153.
4. Department of Health. Variant Creutzfeldt-Jakob disease (vCJD): minimizing the risk of transmission. Health Service Circular HSC 199/178. 13 August 1999. [cited 2013 Jan 17]. Available from: URL: http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/ dh-4012102.pdf.
5. Pennington J, Taylor GP, Sutherland J, Davis RE, Seghatchian J, Allain JP, Williamson LM,. Persistence of HTLV-1 in blood components after leucocyte depletion. Blood 2002; 100: 677-681. (Pubitemid 34761135)
6. Wallis JP, Wells AW, Matthews JN, Chapman CE,. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion 2004; 44: 1025-1032. (Pubitemid 38823809)
7. Borkent-Raven BA, Janssen MP, van der, Poel CL, Schaasberg WP, Bonsel GJ, van, Hout BA,. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010; 99: 55-64.
8. Stramer SL, Foster GA, Dodd RY,. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion 2006; 46: 703-707.
9. Gout O, Baulac M, Gessain A, Semah F, Saal F, Périès J, Cabrol C, Foucault-Fretz C, Laplane D, Sigaux F, de Thé G., Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322: 383-388. (Pubitemid 20042744)
10. Okochi K, Sato H, Hinuma Y,. A retrospective study on transmission of adult T-cell leukaemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46: 245-253. (Pubitemid 14129465)
11. Manns A, Wilks RJ, Murphy E, Haynes G, Figueroa JP, Barnett M, Hanchard B, Blattner WA,. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886-891.
12. Namen-Lopes MS, Martins ML, Drummond PC, Lobato RR, Carneiro-Proietti AB,. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil. Transfus Med 2009; 19: 180-188.
13. Donegan E, Lee H, Operskalski EA, Shaw GM, Kleinman SH, Busch MP, Stevens CE, Schiff ER, Nowicki MJ, Hollingsworth CG, Mosley JW,. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion 1994; 34: 478-483. (Pubitemid 24209657)
14. Tynell E, Andersson S, Lithander E, Arneborn M, Blomberg J, Hansson HB, Krook A, Nomberg M, Ramstedt K, Shanwell A, Bjorkman A,. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ 1998; 316: 1417-1422. (Pubitemid 28211988)
15. Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD,. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV-I/II Collaborative Study Group. Arch Intern Med 1991; 151: 2043-2048.
16. Verdonck K, Gonzales E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E,. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7: 266-281. (Pubitemid 46414075)
17. Kleinman S, Swanson P, Allain J-P, Lee H,. Transfusion transmission of human T-lymphotropic virus types I and II. Serologic and polymerase chain reaction results in recipients identified through look-back investigation. Transfusion 1992; 33: 14-18. (Pubitemid 23040323)
18. Health Protection Agency. Epidemiology-HTLV. 2012. [cited 2013 Jan 17]. Available from: URL: http://www.hpa.org.uk/web/ HPAweb&Page&HPAwebAutoListName/Page/1204100457330.
19. Wenz B, Ortolano GA,. Leucocyte reduction and HTLV-1: is the glass half empty or half full? Blood 2003; 101: 370.
20. Prinsze FJ, Zaaijer HL,. The outcome of donor screening for human T-cell lymphotropic virus infection in the Netherlands. Vox Sang 2012; 102: 198-203.